Literature DB >> 24591670

Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter?

Frits M E Franssen1, Carolyn L Rochester.   

Abstract

It is now recognised that chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with many systemic features. Cardiovascular, metabolic, musculoskeletal and psychological comorbidities contribute to the morbidity and mortality in all stages of the disease. The presence of comorbid conditions has important consequences for disease assessment and management. In addition to treatment of the structural and functional changes in the lungs, clinical programmes for COPD should also assess and manage patients' comorbidities. Thus, there is an increasing need to understand the interaction between existing therapies and comorbidities. Pulmonary rehabilitation is an evidence-based intervention that has been shown to improve clinical outcomes in COPD. However, the impact of comorbidities on outcomes of pulmonary rehabilitation and vice versa is only partially understood. To date, there is limited information on the need for adapting specific interventions in pulmonary rehabilitation to comorbidities or the potential adverse effects of pulmonary rehabilitation in these patients. This article addresses the currently available literature and suggests novel areas for research.

Entities:  

Mesh:

Year:  2014        PMID: 24591670     DOI: 10.1183/09059180.00007613

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  28 in total

1.  Physical Activity Behaviour in People with COPD Residing in Spain: A Cross-Sectional Analysis.

Authors:  Sheila Sánchez Castillo; Lee Smith; Arturo Díaz Suárez; Guillermo Felipe López Sánchez
Journal:  Lung       Date:  2019-11-04       Impact factor: 2.584

Review 2.  Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.

Authors:  Stanley M H Chan; Stavros Selemidis; Steven Bozinovski; Ross Vlahos
Journal:  Pharmacol Ther       Date:  2019-02-26       Impact factor: 12.310

3.  Obesity and extent of emphysema depicted at CT.

Authors:  S Gu; R Li; J K Leader; B Zheng; J Bon; D Gur; F Sciurba; C Jin; J Pu
Journal:  Clin Radiol       Date:  2015-02-19       Impact factor: 2.350

4.  Multimorbidity, frailty and chronic obstructive pulmonary disease: Are the challenges for pulmonary rehabilitation in the name?

Authors:  Anne E Holland; Samantha L Harrison; Dina Brooks
Journal:  Chron Respir Dis       Date:  2016-10-26       Impact factor: 2.444

5.  Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care.

Authors:  Ula Chetty; Gary McLean; Deborah Morrison; Karolina Agur; Bruce Guthrie; Stewart W Mercer
Journal:  Br J Gen Pract       Date:  2017-05       Impact factor: 5.386

6.  Non invasive ventilation as an additional tool for exercise training.

Authors:  Nicolino Ambrosino; Paolo Cigni
Journal:  Multidiscip Respir Med       Date:  2015-04-09

Review 7.  Managing comorbidities in COPD.

Authors:  Georgios Hillas; Fotis Perlikos; Ioanna Tsiligianni; Nikolaos Tzanakis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-01-07

Review 8.  COPD and exercise: does it make a difference?

Authors:  Martijn A Spruit; Chris Burtin; Patrick De Boever; Daniël Langer; Ioannis Vogiatzis; Emiel F M Wouters; Frits M E Franssen
Journal:  Breathe (Sheff)       Date:  2016-06

9.  Enhance Access to Pulmonary Rehabilitation with a Structured and Personalized Home-Based Program-reabilitAR: Protocol for Real-World Setting.

Authors:  Sarah Bernard; Rui Vilarinho; Inês Pinto; Rosa Cantante; Ricardo Coxo; Rosa Fonseca; Sagrario Mayoralas-Alises; Salvador Diaz-Lobato; João Carvalho; Cátia Esteves; Cátia Caneiras
Journal:  Int J Environ Res Public Health       Date:  2021-06-06       Impact factor: 3.390

10.  Phenotypic Variation in Patients with Chronic Obstructive Pulmonary Disease in Primary Care.

Authors:  Emmylou Beekman; Ilse Mesters; Mark G Spigt; Eva A M van Eerd; Rik Gosselink; Rob A de Bie; Onno C P van Schayck
Journal:  Biomed Res Int       Date:  2016-04-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.